Flumatinib

Ascentage Pharma presented olverembatinib's clinical data at ASH 2024, showing efficacy and safety as a second-line therapy for CP-CML patients, especially those failing first-line TKIs. The drug demonstrated promising response rates and safety, with no new safety signals observed.

Olverembatinib shows promise as a second-line therapy for non-T315I-mutant CP-CML, offering high efficacy and safety. Data from a study presented at ASH 2024 revealed significant response rates and clinical benefits, especially for patients previously treated with second-generation TKIs. Ascentage Pharma aims to expedite global development to meet unmet clinical needs.

Olverembatinib shows potential as a safe and effective second-line treatment for chronic-phase chronic myeloid leukemia (CP-CML) patients resistant or intolerant to first-line TKIs, particularly second-generation TKIs. In a study, 74.1% achieved complete cytogenic response (CCyR) and 40.6% major molecular response (MMR) at a median follow-up of 16 months, with no new safety concerns. The treatment, given orally every other day, improved efficacy over time and was well-tolerated.

OBiS Insights pre-meeting ESMO24 report profiles 275 new, unapproved cancer drugs, classified as 40% antibody-based, 37% small molecule, and 23% mixed bag. The report excludes drugs not in abstract titles and will update during the conference. 43% of these drugs were discussed at recent ASCO24 meetings.